Mission-driven science
Turning research advances into better therapies for patients with advanced cancers.
Pioneering company
Using the right team with the right resources to address many of cancer’s toughest challenges.
First-in-Class
Medicine
First-in-class small molecules that disable adaptive responses in many types of cancer
OncoSpherix’s lead compounds disrupt the activation of HIFs by preventing the recruitment of the transcriptional co-activator paralogs p300/CBP to the nascent transcription complex by binding to the CH-1 domain of p300/CBP.
Are you ready to Learn More?
We’re planning clinical trials of agents designed to improve quality of life and survival in patients with a variety of advanced cancers.